“As API suppliers, we've been a bit in the center,” Gomes says. “We see what is going on with our buyers who will be generic or branded drug manufacturers, but we also see what is going on with the earliest stage of the provision chain.Comparison of the application scopes in step with the impurity classes was drawn as indicated in Figure 2.AP